Overall Survival Win for Osimertinib-Chemotherapy in First-Line EGFR-Mutated NSCLC

By News Health
6 hours Ago

(MedPage Today) — First-line osimertinib (Tagrisso) plus chemotherapy significantly improved survival versus osimertinib monotherapy in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC).
Among a total of 557 patients, and…

Source link : https://www.medpagetoday.com/meetingcoverage/iaslc/117347

Author :

Publish date : 2025-09-08 00:32:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Malnutrition and Infection Rates Increase Before IBD Surgery

First-Line Osimertinib Plus Chemo Extends Survival in NSCLC

NSCLC Survival Benefit Seen With EGFR-TKI + Chemo

Disabled doctors consider leaving NHS over shift inflexibility

Fracture Protection May Be Another Benefit of GLP-1 Receptor Agonists

Few Long-Term Bone Consequences After Teen Bariatric Surgery